CDMO Recipharm said that it is now offering services for reformulation of MDIs with new lower global warming potential propellants such as HFA 152a and HFO 1234ze. The company also announced that it has partnered with Prof. Darragh Murnane at the University of Hertfordshire for development of technology around the transition to lower-GWP propellants.
The announcement points out that Recipharm also offers MDI valves that can be used with both of the lower-GWP propellants. Recipharm acquired Consort Medical, the parent company of device maker Bespak, in 2019. That same year, the company launched a program called “Inhalation Solutions” for development of OINDPs from early analytical services through to commercial manufacturing.
Recipharm Head of Advanced Delivery Systems Jean-François Hilaire commented, “We are committed to decarbonization and helping our customers meet their sustainability objectives by transitioning their pMDI products to the new propellants and helping reduce the green house gas (GHG) emissions from their products. Recipharm is working hard to help customers identify and reduce GHG emissions related to both product manufacturing and usage with the common aim of meeting the requirements of the Paris Agreement of limiting global warming to 1.5 degrees Celsius.”
Hilaire added, “Not only that, but as other industries are also asked by regulators to phase-out propellants with higher GWP, it’s likely that the existing propellants will become less available and more costly. It is therefore important that we prepare to work with new propellants to safeguard the supply of pMDIs to patients. 2022 is an exciting year for Recipharm and our investment in these new manufacturing lines will support us in introducing more sustainable propellants to our pMDI production.”
Murnane said, “We are excited about the next phase of working with Recipharm. We’re really looking forward to addressing the challenges of reformulation for low-GWP inhalation products with the Recipharm team.”
